These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19133603)

  • 1. First-line therapeutic strategies in metastatic colorectal cancer.
    Davies JM; Goldberg RM
    Oncology (Williston Park); 2008 Nov; 22(13):1470-9. PubMed ID: 19133603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Landherr L; Nagykálnai T
    Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Chu E
    Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
    [No Abstract]   [Full Text] [Related]  

  • 5. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metastatic colorectal cancer: adjournments from ESMO 2006].
    Bonetti A; Cascinu S; Falcone A; Maiello E; Zaniboni A; Aschele C
    Tumori; 2006; 92(6):1-12. PubMed ID: 17262903
    [No Abstract]   [Full Text] [Related]  

  • 8. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
    Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
    Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
    Cohen MS; Al-Kasspooles MF; Williamson SK; Henry D; Broward M; Roby KF
    Ann Surg Oncol; 2010 Jan; 17(1):296-303. PubMed ID: 19707832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of new agents in the treatment of colorectal cancer.
    Folprecht G; Köhne CH
    Oncology; 2004; 66(1):1-17. PubMed ID: 15031593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
    Jackson NA; Barrueco J; Soufi-Mahjoubi R; Marshall J; Mitchell E; Zhang X; Meyerhardt J
    Cancer; 2009 Jun; 115(12):2617-29. PubMed ID: 19382200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
    Maung K; Lee D; DeGrendele HC; Schilsky R; Chu E; Jain VK; Copur S
    Clin Colorectal Cancer; 2002 Nov; 2(3):140-5. PubMed ID: 12482329
    [No Abstract]   [Full Text] [Related]  

  • 13. [Capecitabine and irinotecan].
    Gasperoni S
    Suppl Tumori; 2004; 3(4):S107-8. PubMed ID: 15206231
    [No Abstract]   [Full Text] [Related]  

  • 14. New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Cassidy J; Hochster H
    Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A review of chemotherapy for metastatic colon cancer].
    Díez-Fernández R; Salinas Hernández P; Girón-Duch C
    Farm Hosp; 2006; 30(6):359-69. PubMed ID: 17298193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common side effects and interactions of colorectal cancer therapeutic agents.
    Holt K
    J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
    [No Abstract]   [Full Text] [Related]  

  • 17. New developments in systemic chemotherapy in advanced colorectal cancer.
    Cats A
    Scand J Gastroenterol Suppl; 2003; (239):78-86. PubMed ID: 14743888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the development of novel treatments for colorectal cancer.
    Hoff PM; Pazdur R
    Oncology (Williston Park); 2004 May; 18(6):705-8. PubMed ID: 15214591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.